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ABSTRACT 
Cardiac hypertrophy is the result of increased myocardial cell size responding to an increased 
workload and developmental signals. These extrinsic and intrinsic stimuli as key drivers of 
cardiac hypertrophy have spurred efforts to target their associated signaling pathways. The 
extracellular signal-regulated kinases 1/2(ERK1/2), as an essential member of mitogen-activated 
protein kinases (MAPKs), has been widely recognized for promoting cardiac growth. Several 
modified transgenic mouse models have been generated through either affecting the upstream 
kinase to change ERK1/2 activity, manipulating the direct role of ERK1/2 in the heart, or 
targeting phosphatases or MAPK scaffold proteins to alter total ERK1/2 activity in response to 
an increased workload. Using these models, both regulation of the upstream events and 
modulation of each isoform and indirect effector could provide important insights into how 
ERK1/2 modulates cardiomyocyte biology. Furthermore, a plethora of compounds, inhibitors, 
and regulators have emerged in consideration of ERK, or its MAPKKs, are possible therapeutic 
targets against cardiac hypertrophic diseases. Herein, is a review of the available evidence 
regarding the exact role of ERK1/2 in regulating cardiac hypertrophy and a discussion of 
pharmacological strategy for treatment of cardiac hypertrophy.  
Key words: ERK1/2, cardiac hypertrophy, cardiomyocyte, genetic approaches, 
pharmacological strategy 
 
 
INTRODUCTION 
The mammalian heart is a muscular pump that circulates blood throughout the body to 
maintain perfusion of peripheral organs, which meets their demand during both regular and 
stressful conditions. In response to an increased workload, enlargement of the heart occurs and is 
defined as an increase in heart size without changes in myocyte number. Physiological 
hypertrophy observed in normal growth or trained athletes is considered an adaptive and 
compensatory response to maintain cardiac function and improved cardiac contractility. By 
contrast, cardiac hypertrophy under pathological conditions, such as ischemic heart disease, 
hypertension, and heart failure, is referred to as pathological hypertrophy. This type of 
hypertrophy is associated with the production of high levels of hemodynamic overload, 
interstitial fibrosis, and myocardial cell damage and loss [1, 2]. Because cardiac hypertrophy 
plays a central role in cardiac remodeling and is an independent risk factor for cardiac events, 
understanding the molecular mechanisms is vital.  
Previous studies have shown that a group of medical genetic syndromes referred to as 
RASopathie are caused by germline mutations in genes that encode components or regulators of 
the RAS-RAF-MEK-ERK pathway, which include neurofibromatosis type 1, Noonan syndrome, 
Costello syndrome, and cardio-facio-cutaneous syndrome [3]. These patients suffered from 
cardiomyopathies suggesting that the RAS/MAPK pathway is critical to normal heart 
development. Moreover, before mouse genetics entered the mainstream of experiments, studies 
were conducted mainly on cultured neonatal rat cardiomyocytes or inadequate “myocyte-like” 
cell lines which discovered the activation of the ERK1/2 pathway under the hormone and 
mechanical stretch in the heart, suggesting a direct causation between ERK1/2 signaling and the 
hypertrophic response [4, 5]. To support this hypothesis, the use of dominant negative MEK1, 
antisense oligonucleotides against ERK1/2, dephosphorylation of ERK1/2, and pharmacologic 
inhibitors of MEK1/2 provided convincing data, indicating that MEK1-ERK1/2 is both necessary 
and sufficient for cardiac hypertrophy [6–10]. Autophosphorylation of ERK1/2 on Thr188 was 
also observed in isolated cardiomyocytes induced by hypertrophic stimulus [11]. Although 
considerable evidence elucidates that the activated MEK1/2-ERK1/2 can regulate cardiac 
hypertrophy in vitro, the results of other similarly designed culture-based studies are quite 
different [12, 13]; one study even suggested that ERK1/2 activation is anti-hypertrophic [14]. In 
addition to traditional 2-dimensional (2D) in vitro systems, three-dimensional (3D) tissue models 
have also offered new tools in the study of cardiovascular disease recently [15]. In response to 
3D conditions, the activation of ERK1/2 was observed during cardiomyogenesis, and the 
phosphorylation of ERK1/2 was higher compared to cells on 2D films, which provides insight 
into ERK1/2 pathways driving heart development [16, 17]. With regard to the whole organ 
phenomenon in a dynamically changing neuroendocrine environment under cardiac hypertrophy 
and heart failure, culture-based or tissue-engineering approaches have only provided some basic 
physiological parameters within a largely 2D or 3D environment [18]. However, these 
approaches will always be necessary because of the simplified process established in a largely 
isolated system and temporal relationships. More recently, a new method, known as 
mathematical optimization framework, also analyzed the complex ERK1/2 cascade in 
cardiomyocytes to find efficient adjustment screws for this cascade that is important for 
cardiomyocyte survival and maladaptive heart muscle growth [19]. 
In this review, the focus was on the main thread of the RAS-RAF-MEK-ERK pathway and 
summarize the more recent knowledge about the functional activity of ERK pathway in the 
cardiac organ to reveal the exact role of ERK1/2 in regulating cardiac hypertrophy.  Also, the 
latest scientific results of addressing ERK signaling as a therapeutic target for the treatment of 
cardiac hypertrophy is discussed. 
 
COMPONENTS AND REGULATION OF THE ERK CASCADE 
As ERK1 and ERK2 are 83% identical in sequence and share most of the same signaling 
activities, they are usually referred to as ERK1/2 [20]. However, these two proteins are not 
entirely functionally redundant. For instance, ERK1 knockout animals appear normal and are 
viable, while ERK2 deletion results in embryonic lethality [21]. In cardiomyocytes, the canonical 
ERK1/2 signal cascade is initiated by the activation of the small G protein RAS in the cell 
membrane, which leads to the recruitment and activation of RAF-1 (MAP3K), which further 
phosphorylates the dual-specificity protein kinases MEK1/2 (MAP2K); eventually, MEK1/2 
characteristically activate ERK1/2 (MAPK) by phosphorylating the threonine-glutamate-tyrosine 
(TEY) motif in the phosphorylation loop. Active ERK is then released from the MEK and 
phosphorylates a wide array of cytoplasmic substrates. Alternatively, activation of ERK is 
translocated to the nucleus and phosphorylates numerous transcription factors, which result in 
the induction of growth and proliferation and in the prevention of cell death [22]. Furthermore, 
the specificity of ERK biological effects is influenced by many factors, including (i) duration and 
strength of the signals, (ii) interaction with various scaffold proteins, (iii) subcellular localization, 
(iv) extensive cross-talk and interplay between the ERK cascade and other intracellular signaling 
pathways, and (v) presence of several similar isoforms at each tier of the cascade [23]. Although 
many of these mechanisms could independently determine signaling specificity and magnitude 
of the signaling outcome, they often work in coordination with each other to ensure proper 
downstream effects. Additionally, the pro-hypertrophic, pro-survival and pro-death effects of 
ERK1/2 converge on mitochondria upon their crucial roles in metabolism of cardiomyocyte. In 
response to types of stimuli, ERK1/2 can modulate mitochondria-mediated cardiomyocyte 
function directly through the interaction with mitochondria [24], or indirectly, by 
activation/inhibition of ERK-dependent downstream signaling molecules or mediators [25–28]. 
Finally, the inactivation of ERKs is regulated by various phosphatases, including dual-specificity 
MAPK phosphatases (MKPs), protein serine/threonine phosphatases (PPs), and protein tyrosine 
phosphatases (PTP) [29, 30].  
 ERK1/2 AND CARDIAC HYPERTROPHY 
Studying the role of the RAS-RAF-MEK-ERK pathway in the heart, did not, herein, satisfy 
a detailed understanding of the physiological function of the cascade, which revealed that 
cardiomyocytes are isolated from their physiological environment, the present investigation  
focuses on the emergence of genetic approaches in mice using gained or lost functional mutants 
(Fig. 1). 
 
Targeting upstream kinase 
The previously published H-Ras-V12 transgenic model with overstimulating of the RAS 
hinted at the trend of decompensation and dilatation of the heart and developed a chain of events 
that contributed to the pathogenesis of cardiovascular disease [31–33]. Subsequently, Wei et al. 
[34] demonstrated that discontinuing overactivation of this pathway after the onset of 
cardiomyopathy could lead to improved survival and cardiomyopathy lesion scores, suggesting 
the reversibility of early pathogenic hypertrophy. More recently, the possible anti-hypertrophic 
effect of RAS inhibition in the setting of pressure-overload cardiac hypertrophy in rats was 
examined [35]. After pressure-overload induction and Ras-mutant gene transfer, the hypertrophic 
degrees of the heart in both Ras mutants were similar. However, the Ras-Val12 mutant increases 
LV systolic diameter and reduces LV fractional shortening compared to control and dominant 
negative mutant N17-DN-Ras (DN-Ras). Moreover, DN-Ras exhibited some similarities with 
physiologic hypertrophy, especially the lower expression of markers of pathologic cardiac 
hypertrophy. Although these studies used different promoters to drive RAS expression, the same 
constitutively activated RAS mutants were generated, indicating that the inactivation of Ras is 
cardioprotective rather than anti-hypertrophic. Ras directly activates Raf-1, which may 
subsequently lead to MEK1-ERK1/2 activation. It also activates other intracellular signaling 
pathways. Importantly, its activation is involved in pathological changes in sarcoplasmic 
reticulum calcium handling [36, 37]. 
Activating mutations in the serine-threonine kinase Raf cause cardiac hypertrophy and 
contribute to Noonan syndrome in humans. Heterozygous Raf1L613V mice were generated and 
exhibited eccentric cardiac hypertrophy, aberrant cardiac fetal gene expression, and 
decompensation following pressure overload, but treatment of these mice with MEK inhibitors 
(PD0325901) or constitutive deletion of ERK effector (RSK3) rescued Raf-mediated cardiac 
hypertrophy and other phenotypic abnormalities [38, 39]. In addition, a dominant negative form 
of Raf-1 animals had obvious resistance to the development of cardiac hypertrophy and 
hypertrophic gene induction in response to pressure overload [40]. Both groups found that, while 
Raf-1 kinase activity was essential for cardiac hypertrophy, enhanced MEK-ERK activity was 
critical for causing RAF1-mutant phenotypes. However, recently, Yin et al. showed that left 
ventricular hypertrophy was due to the interplay of cardiac cell types [41]. Using inducible 
Raf1L613V expression, mutant RAF1 expression in cardiomyocytes enhanced Ca2+ sensitivity 
and cardiac contractility rather than hypertrophy. By contrast, endothelial/endocardial (EC)-
restricted mutant expression does not affect contractility, but evokes hypertrophy. Moreover, 
aberrant RAF1 activity in cardiomyocytes or cardiac fibroblasts, but not ECs, contributes to 
pressure overload-induced fibrosis in Noonan syndrome cardiomyopathy. These results support a 
paradigm shift away from the myocyte-centric view of cardiac development and disease. 
Even though RAS transgenic mice exhibited cardiac hypertrophy associated with 
cardiomyopathy, MEK1 transgenic mice showed a stable concentric hypertrophy without any 
signal of decompensation up to 12 months of age [42]. Furthermore, these mice expressing 
activated MEK1 showed a dramatic increase in cardiac function measured by echocardiography 
and isolated working heart preparation, and there was activation of ERK1/2, but not p38 or JNK. 
In addition, MEK1 transgenic mice showed resistance to ischemia/reperfusion-induced 
apoptosis. These outcomes suggest that MEK-ERK not only sufficiently induces normally 
hypertrophic response, but that it also has a bearing on partial resistance to apoptosis. 
Taken together, these results support that the RAS-RAF-MEK-ERK pathway is generally 
regarded as pro-hypertrophic and suggest that sustained cascade activation also plays a 
cardioprotective role in the heart. Furthermore, the closer the upstream kinase is to ERK, the 
stronger the correlation with hypertrophic process. This may be because the initial upstream 
kinase is more susceptible to interference from other factors.  
 
Targeting ERK1/2 
In view that evidence of non-redundancy is apparent from isoform-specific ERK targeted 
mice, overexpression of intrinsically active ERK1 and ERK2 in the heart were generated to 
further test the effects of ERK1/2. A recent study reported transgenic mice expressing activated 
ERK1 under the transcriptional control of the α-MHC promoter — which, similar to the 
observations in hypertrophy, is phosphorylated on both the TEY and the Thr207 motifs and is 
overexpressed at pathophysiological levels — developed a modest adaptive hypertrophy with 
increased contractile function and without fibrosis [43]. Nevertheless, another recent study 
demonstrated that volume overload-induced eccentric hypertrophy is associated with reduced 
cardiac ERK1/2 activation while phosphorylation of other MAPKs was unaffected in vivo. 
However, transgenic mice with cardiomyocyte-specific ERK2 overexpression did not alter left 
ventricular dilation and hypertrophy [44]. Importantly, Molkentin et al. [18] found that high 
levels of ERK2 overexpression in the heart from two independent transgenic lines with the same 
α-MHC promoter did not induce hypertrophy. However, MEK1 transgenic mice crossed with 
ERK2 transgenic mice showed synergistic hypertrophy. Although ERK2 seems to be dominant in 
the results of the knockout experiment, the single overexpression of these two kinds of MAPK 
appears inconsistent, and the relationship between MEK1/2 and ERK2 is likely to be close. 
These results indicate that ERK1 may induce the hypertrophic effect after the inhibition of 
MEK1/2. Further, a novel ERK2 autophosphorylation site, other than TEY phosphorylation, was 
found on Thr188 after stimulation with pressure overload and in failing human hearts [11]. The 
equivalent phosphorylation was also discovered on EKR1 at Thr207 [45, 46]. The authors 
generated several lines of transgenic mice overexpressing ERK2 with mutations at Thr188. 
Compared with baseline wild type mice, no hypertrophy was observed in these mice [11]. After 
pressure overload, the ERK2T188D (gain-of-function ERK) mice showed more striking 
hypertrophy, not the ERK2T188A or ERK2T188S (phosphorylation-deficient ERK) mice. This 
mechanism depends on upstream signals — specifically, activation of Gq-coupled receptors, 
which release Gβγ; activation of the entire Raf-MEK-ERK cascade; subsequent phosphorylation 
of ERK1/2 within the TEY motif; and ERK dimerization. The integration of these signaling 
events leads to autophosphorylation of ERK2 at Thr188. In addition, the phosphorylation of 
Thr188 is related to the pathological morphology of hypertrophy [47]. It is generally believed 
that the specific role of Thr188 phosphorylation of ERK1/ 2 in vivo was to transform adaptive 
ERK signals into maladaptive signals. However, this notion is based on a study of mice 
overexpressing ERK2 Thr188 mutants, which may eliminate catalytic activity of ERK. 
Contrary to the gain of function of ERK1/2, some reports on ERK knockout mice suggested 
that ERK1/2 signaling may not be necessary to mediate cardiac growth in vivo. ERK1 null (–/–) 
and ERK2 null (+/–) mice showed no reduction in cardiac hypertrophy response to pathologic 
stimulus-induced by transverse aortic constriction (TAC) or to physiologic stimulus-induced by 
swimming [48]. Moreover, mice lacking all ERK1/2 protein in the heart (ERK1–/– ERK2fl/fl-
Cre) were generated. After eliminating both isoforms, the heart still increased in weight with 
both aging and pathological stress stimulation, where the heart showed spontaneous dilatation 
and the cardiomyocytes showed spontaneous lengthening [49]. Another study examined the 
cardiomyocyte-specific deletion of the ERK2 gene (ERK2cko mice). Following short-term 
pathological hypertrophic stresses, the mutant mice showed attenuated hypertrophic remodeling 
characterized by a blunted increase in the cross-sectional area of individual myocytes. However, 
the absence of ERK2 did not affect physiological hypertrophy induced by exercise [50].  
Above all, these results suggest that either ERK1/2 are not critical for mediating cardiac 
hypertrophy under pathophysiologic stress or the remaining ERK1/2 activity in each gene-
targeted mouse model was sufficient to mediate the signaling events required to drive the 
hypertrophic response. This outcome places ERK at the crossroads of cardiac hypertrophic 
signaling pathways and raises the possibility that different isoforms of ERK may play different 
roles in regulating the growth of cardiac myocytes.  
 
Targeting phosphatases and MAPK scaffold proteins 
Due to the high embryonic lethality, it was difficult to generate ERK1–/– ERK2+/– mice (3 
of 4 alleles deleted) to address the necessity of ERK1/2 signaling in mediating cardiac 
hypertrophy. Therefore, other approaches are desirable to more effectively alter total ERK1/2 
activity within the heart. Dual-specificity phosphatases (DUSPs), the largest family of MAPK-
selective phosphatases, act to dephosphorylate both the p-Ser/Thr and -Tyr residues that are 
essential for cytosolic and/or nuclear MAPK activity. A precedent for these phosphatases 
appeared with the description of DUSP6–/– mice [51]. An increase in basal ERK1/2 
phosphorylation in the absence of DUSP6 was identified, but no effect was observed on other 
MAPKs after stimulation. DUSP6–/– mice with larger hearts was not due to hypertrophy, but 
rather to hypercellularity of the myocytes. A recent study confirmed a similar finding in the 
zebrafish heart by suppressing the Dusp6 function, which showed that DUSP6 attenuated 
Ras/MAPK signaling during regeneration, and inactivation of DUSP6 could enhance cardiac 
repair [52]. Opposite to the activation of ERK1/2, multiple lines of DUSP6 contained in the 
mouse heart were specifically generated [48]. Similar to ERK1 null (–/–) and ERK2 null (+/–) 
mice, low-, medium-, and high-Dusp6 Tg mice showed no reduction in hypertrophy after 
pressure overload stimulation, neuroendocrine agonist infusion, or physiologic exercise 
stimulation, though the activation of all cardiac ERK1/2 at baseline were nearly eliminated. 
Notably, a phosphatase known as DUSP8 has drawn attention recently. DUSP8–/– mice 
increased ERK1/2 phosphorylation and were mildly hypercontractile at baseline with the 
concentric remodeling of the heart, which provided prolonged protection from progressing 
towards heart failure in two surgery-induced disease models [53]. While cardiac-specific 
overexpression of DUSP8 produced spontaneous eccentric remodeling with heart failure, 
overexpression of DUSP8 in the heart caused dephosphorylation of all three major MAPK 
terminal effectors. Overall, although these studies suggest that ERK1/2 manipulated by DUSP6 
and DUSP8 are not required for mediating hypertrophy per se, one critical point to consider is 
that other DUSPs such as DUSP2, -4, -5, -7, and -9 also dephosphorylate ERK1/2 [54]. While 13 
DUSP proteins are dedicated to regulating and recycling the MAPKs, each appears to have a 
highly specialized regulatory role. 
Given that MAPK scaffolding proteins enable the formation of specific signaling complexes 
and subcellular localization in the activation of an MAPK cascade, many studies of genetic 
mouse models, specifically MAPK scaffolding proteins, have further reinforced a direct role for 
ERK1/2 pathway in stress-induced cardiac hypertrophy. Scaffold proteins tether MAPK/ERK 
signaling at the sarcomere and plasma membrane in the cardiac muscle and regulate ERK 
signaling strength and duration [55]. As such, ANKRD1, which conducts the components of the 
sarcomere-associated biomechanical sensors, can be markedly induced by various hypertrophic 
stimuli and in distinct animal models of hypertrophy. ANKRD1-overexpressing transgenic mice 
developed less hypertrophy, and no differences were evident in heart function compared to wild-
type mice in TAC- and isoproterenol-induced models [56], which were mediated by the 
inhibition of ERK1/2 and TGF-β pathways. Conversely, striking cardiac hypertrophy with 
reactivation of the cardiac fetal gene program induced by chronic PE infusion in wild-type mice 
was completely eliminated in ANKRD1 null mice via ANKRD1-ERK-GATA4 complex to 
regulate hypertrophic responses [57]. This phenomenon may be caused by different hypertrophic 
stimuli. Respectively, IQGAP1, which bind to the plasma membrane, played a part in the 
maintenance of cardiomyocyte physiology and the induction of adaptive hypertrophy. IQGAP1-
null mice initially developed compensatory hypertrophy and unaltered basal heart function in 
response to pressure overload, but with a prolonged stimulus, they showed acceleration towards 
the development of maladaptive hypertrophy resulting in a decrease of cardiac contractility [58]. 
These results emphasize that different scaffold proteins may mediate the spatial regulation of 
ERK1/2 activation, which in turn determines the substrate specificity of pathological states 
associated with cardiac hypertrophy. Additionally, MAPK scaffolds, such as MP1 [59] and 
DYRK1A [60], have been characterized in the heart, but their role in cardiac remodeling has not 
yet been addressed. By extension, readers can see several excellent recent reviews on this issue 
[61, 62]. 
 
PHARMACOLOGICAL STRATEGY FOR THE TREATMENT OF CARDIAC 
HYPERTROPHY 
Despite substantial advances, there is still a major demand for finding novel therapeutic 
strategies to use in the hypertrophic process of cardiac remodeling and cardiac events. Although 
ERK activation events need to be investigated further and refined in detail, ERK or its MAPKKs, 
is a possible therapeutic target for a pharmacological strategy against cardiac hypertrophic 
diseases. If the intrinsic manipulation of ERK is insufficient to reliably achieve complete 
remission, an obvious alternative strategy is to target extrinsically potential compounds, 
inhibitors, or regulators.  
 
Compounds 
Recent works are underway to discover compounds that inhibit this pathway and thus 
provide a potential therapeutic agent that could attenuate cardiac growth. Traditional Chinese 
medicine has been reported to be effective for the treatment of cardiac hypertrophy in animal 
models, such as Baicalein and Bu-Shen-Jiang-Ya [63] decoction (BSJYD). Baicalein, known for 
its antibacterial, antiviral, and anti-inflammatory effects, protects against cardiac hypertrophy 
and fibrosis in response to chronic pressure overload by regulating the MEK-ERK1/2 signaling 
pathway [63]. Additionally, BSJYD treatment decreases systolic blood pressure and heart rate 
efficiently and suppresses the hypertension-induced cardiac hypertrophy associated with the 
suppressive effect of BSJYD on the EKR signaling pathway [64]. Other compounds were also 
reported to target the ERK pathway. Sun et al. [65] showed that Gentisic acid attenuates pressure 
overload-induced cardiac hypertrophy and fibrosis in mice through inhibition of the ERK1/2 
pathway. Additionally, Li et al. [66] demonstrated that selumetinib could attenuate pathological 
and physiological cardiac hypertrophy in vivo caused by pressure overload and swimming. 
In short, these preclinical studies encourage the emergence of more effective compounds to 
target cardiac hypertrophy with aberrant ERK activation. 
 
Inhibitors 
Developed for the treatment of various cancers, kinase inhibitors are also used to reduce 
excessive signal activation in cardiac hypertrophy. One study that explored the effects of the 
MEK inhibitor of Pimasertib on cardiac hypertrophy and heart failure showed a reversible effect 
of Pimasertib on a transgenic model expressing an activated MET receptor, which was attributed 
to the inhibition of ERK1/2 pathway [67]. Several in vitro studies have also explored the effects 
of MEK inhibitor effects on cultured cardiomyocytes. Two of the most commonly utilized are 
PD98059 and U0126. PD98059 reversed leukemia inhibitory factor (LIF)-induced 
cardiomyocyte hypertrophy [68]. Similarly, U0126 blocked cardiomyocyte growth induced by 
endothelin-1 and phenylephrine [69]. As available MEK inhibitors for the ERK signaling 
pathway, these agents target regions distinct from the ATP pocket. However, these two inhibitors 
inhibit all MEKs upstream of the ERKs, including MEK1, MEK2, and MEK5. More recently, a 
newly potent and selective MEK inhibitor called TAK733 was confirmed to suppress 
norepinephrine or phenylepinephrine-induced cardiomyocyte hypertrophy through the 
depression of MEK-ERK signaling [70]. These studies support the role of MEK-ERK cascade in 
promoting hypertrophy, but the inherent non-selectivity of some inhibitors should not be ignored 
because of their effects on MEK5. 
 
Regulators 
It is common knowledge that MAPK pathways are largely associated with G protein-
coupled receptor (GPCRs)-mediated signaling. Belonging to cell membrane receptors, GPCRs 
interact with G‐ proteins to activate multiple downstream intracellular cascades and in turn 
modulate subsets of effector proteins [71]. Regulators of G‐ protein signaling (RGS) proteins are 
negative regulators of G protein‐ mediated signaling that serve as GTPase‐ activating protein for 
heterotrimeric G proteins. Recently, accumulating studies have demonstrated that RGS proteins 
can regulate cardiac hypertrophy independent of GTPase-activating protein activity. Among 
them, RGS3 [72], RGS5 [73], RGS10 [74], RGS12 [75], and RGS14 [76] protect against 
pressure overload-induced hypertrophic response and improve cardiac function by inhibiting 
MEK–ERK1/2 signaling. Notably, unlike most overexpression approaches leading to beneficial 
effects on the heart, RGS12-defcient hearts showed a decreased cardiomyocyte cross area 
without predisposing the heart to adverse remodeling and failure. Although RGS10, RGS12 and 
RGS14 belong to the R12/D subfamily, the reason for such opposing responses is not completely 
understood. Considering the anti-hypertrophic effect attributed to some RGS proteins through 
MEK–ERK1/2 signaling, their potential as targets for therapeutic intervention warrants further 
examination. 
 
CONCLUSIONS 
In summary, although the ERK cascade is a major signaling component and regulates many 
distinct cellular processes, the functional role of the ERK1/2 in the heart still presents a potential 
dilemma. As this review shows, many current approaches are based solely on opposite ways to 
dissect the cardiac disease states, such as cell culture versus mouse genetics, direct versus 
indirect manipulation of ERK1/2, and gain versus loss of function. However, the ERK cascade is 
mainly regulated at several levels by different phosphatases and scaffold proteins, other signaling 
pathways, subcellular localization, and even different isoforms per se. Many of these 
mechanisms can work together to determine the final specificity of the cascade. While 
uncontrolled activation of RAS-RAF-MEK-ERK signaling may lead to cardiac hypertrophy, 
inhibiting the pathway may also make the heart more susceptible to stress induced 
cardiomyocyte death. Therefore, to unravel the ERK1/2 mechanisms, more sophisticated model 
systems are required, which will help us to make sure the critical role of ERK1/2 and the ensuing 
effects in the heart. In light of the lack of uniform results in ERK biology in cardiac hypertrophy, 
translation of the knowledge about pro-hypertrophic signaling pathways may lead to both 
exciting and challenging clinical insights. 
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Figure 1. Schematic diagram of extracellular signal-regulated kinases (ERK) pathway and 
mitogen-activated protein kinase (MAPK)-associated genetic mouse models. In cardiomyocytes, 
the canonical ERK1/2 signal cascade is initiated by the activation of the small G protein RAS in 
the cell membrane, which leads to the recruitment and activation of RAF-1, which further 
phosphorylates the dual-specificity protein kinases MEK1/2; eventually, MEK1/2 
characteristically activate ERK1/2. In response to growth factors, hormones, and mechanical 
stress, the RAS-RAF-MEK-ERK pathway, dual-specificity phosphatases and scaffold proteins 
were overexpressed or inhibited in the mouse to change ERK1/2 activity, which examines the 
connection between ERK activation and cardiac hypertrophy. 

